|Product Overview:||Recombinant Rat Tnfsf11(Arg72-Asp318) fused with His tag at N-terminal was expressed in CHO.|
|Description:||B7-H1, also known as PD-L1 and CD274, is an approximately 65 kDa transmembrane glycoprotein in the B7 family of immune regulatory molecules. Mature cynomolgus B7-H1 consists of a 220 amino acid (aa) extracellular domain (ECD) with two immunoglobulin-like domains, a 21 aa transmembrane segment, and a 30 aa cytoplasmic domain. Within the ECD, cynomolgus B7-H1 shares 92%, 72%, and 72% aa sequence identity with human, mouse, and rat B7-H1, respectively. In addition, cynomolgus B7-H1 shares 98%, 94%, 94%, 88%, 78%, 98%, 95%, 94%, and 94% aa sequence identity with rhesus macaque, chimpanzee, sumatran orangutan, white-tufted-ear marmoset, Garnett's greater bushbaby, olive baboon, green monkey, western lowland gorilla, and northern white-cheeked gibbon B7-H1, respectively. B7-H1 is expressed on inflammatory-activated immune cells including macrophages, T cells, and B cells, keratinocytes, endothelial and intestinal epithelial cells, as well as a variety of carcinomas and melanoma. B7-H1 is a B7 ligand and binds to B7-1/CD80 and PD-1 receptors on T cells. It suppresses T cell activation and proliferation and induces the apoptosis of activated T cells. It plays a role in the development of immune tolerance by promoting T cell anergy and enhancing regulatory T cell development. B7-H1 favors the development of anti-inflammatory IL-10 and IL-22 producing dendritic cells and inhibits the development of Th17 cells. In cancer, B7-H1 provides resistance to T cell mediated lysis, enhances EMT, and enhances the tumorigenic function of Th22 cells. B7-H1/PD-1 coinhibitory pathway was exploited therapeutically resulting in remarkable outcomes with 20-90% response in various types of cancer.|
|Predicted N Terminal:||His|
|Form:||Lyophilized from a 0.2 μm filtered solution in NaH2PO4, NaCl and EDTA with BSA as a carrier protein.|
|Bio-activity:||Measured by its ability to induce osteoclast differentiation of RAW 264.7 mouse monocyte/macrophage cells. The ED50 for this effect is 2.5-15 ng/mL.|
|Molecular Mass:||Predicted Molecular Mass: 29 kDa
SDS-PAGE: 33-38 kDa, reducing conditions
|Endotoxin:||<0.1 EU per 1 μg of the protein by the LAL method.|
|Purity:||>85%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.|
|Storage:||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 centigrade as supplied.
1 month, 2 to 8 centigrade under sterile conditions after reconstitution.
3 months, -20 to -70 centigrade under sterile conditions after reconstitution.
|Reconstitution:||Reconstitute at 100 μg/mL in PBS containing at least 0.1% human or bovine serum albumin.|
|Gene Name:||TNFSF11 tumor necrosis factor (ligand) superfamily, member 11 [ Homo sapiens ]|
|Synonyms:||TNFSF11; tumor necrosis factor (ligand) superfamily, member 11; tumor necrosis factor ligand superfamily member 11; CD254; ODF; OPGL; RANKL; TRANCE; osteoprotegerin ligand; osteoclast differentiation factor; TNF-related activation-induced cytokine; receptor activator of nuclear factor kappa B ligand; receptor activator of nuclear factor kappa-B ligand; sOdf; OPTB2; hRANKL2;|
Price does not include shipping and packaging costs.Request quote for final price.